ST Pharm Co.,Ltd. (KOSDAQ:237690)

South Korea flag South Korea · Delayed Price · Currency is KRW
83,300
-2,300 (-2.69%)
Jul 11, 2025, 3:30 PM KST
-13.59%
Market Cap 1.68T
Revenue (ttm) 274.45B
Net Income (ttm) 29.52B
Shares Out 20.15M
EPS (ttm) 1,488.44
PE Ratio 55.96
Forward PE 41.01
Dividend 500.00 (0.58%)
Ex-Dividend Date Dec 27, 2024
Volume 106,580
Average Volume 111,260
Open 86,500
Previous Close 85,600
Day's Range 83,200 - 86,700
52-Week Range 66,600 - 120,800
Beta 0.73
RSI 57.51
Earnings Date Jul 25, 2025

About ST Pharm

ST Pharm Co.,Ltd., provides custom manufacturing services for active pharmaceutical ingredient and intermediates in South Korea and internationally. The company offers small molecule and generics, an ingredient for treating viral infections; oligonucleotide based products, such as siRNA/microRNA, antisense, aptamer, decoys, and other novel oligos; monomer; and mRNA for vaccines and therapeutics. It also offers pre-clinical and bioanalytical R and D solutions. The company was formerly known as Samchully Pharmaceutical Company., Ltd. ST Pharm Co.... [Read more]

Industry Medical - Pharmaceuticals
Sector Healthcare
Founded 1983
Employees 655
Stock Exchange KOSDAQ
Ticker Symbol 237690
Full Company Profile

Financial Performance

In 2024, ST Pharm's revenue was 273.75 billion, a decrease of -3.94% compared to the previous year's 284.99 billion. Earnings were 34.71 billion, an increase of 77.27%.

Financial Statements

News

There is no news available yet.